Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia and Latvia, in addition to Israel. 

This new agreement builds upon the successful long-term partnership between Alnylam and Medison in Israel and will allow Alnylam to utilize Medison's unique multi-regional platform to ensure that Alnylam's innovative RNA interference (RNAi) therapeutics, such as ONPATTRO^® (patisiran), GIVLAARI^® (givosiran), and OXLUMO^® (lumasiran) are made available across additional countries in Europe. This expanded agreement is intended to ensure more efficient and effective commercialization. GIVLAARI® and OXLUMO® have already been approved for reimbursement in Poland, and Alnylam and Medison will work together to obtain additional reimbursements in the territories.

"We are delighted to extend our existing relationship with Medison, which will enable us to enhance our presence and bring the benefits of Alnylam's innovative RNAi therapeutics to patients in Central and Eastern Europe," said Norton Oliveira, Senior Vice-President and Head of Partner and Emerging Markets at Alnylam. "Medison is already one of our most significant partners, and their team has a wealth of experience to offer across our new markets. We look forward to continuing our collaboration and transforming more patients' lives together."

"The trust Alnylam shows in Medison's multi-regional commercial platform allows us to broaden patient access to Alnylam's highly innovative therapies across more countries," said Meir Jakobsohn, Founder and CEO of Medison. "Expanding our successful partnership will enable us to provide access to patients across Central and Eastern Europe who might otherwise not have access to these innovative treatment options."

"We are privileged to expand the access of Alnylam's groundbreaking treatments to additional markets. "Medison's multi regional platform makes us the partner of choice for emerging biotech companies seeking to make their innovative products available in international markets for the benefit of patients suffering from rare, debilitating disease", said Gil Gurfinkel, VP Corporate Development at Medison